2025年医药融资强势反弹，731笔、同增31%，市场信心又变强了

Core Insights - The innovation in drug development is fundamentally about improving trial and error efficiency, with Chinese companies currently demonstrating the strongest efficiency historically in terms of time and globally in terms of space [1] - The biopharmaceutical industry is showing a significant recovery in 2025, with a notable shift in capital market focus from "chasing hotspots" to "valuing innovation" [1] Financing Trends - In 2025, the domestic biotechnology and pharmaceutical industry experienced a "double growth" in financing, with 731 financing events, a 31% increase from 2024, and a total financing amount of approximately 593.78 billion RMB, a 17% year-on-year increase [2][4] - The average single financing amount reached 82.13 million RMB, indicating a steady improvement in capital allocation efficiency [4] Historical Context - The industry saw a peak in 2021 with financing reaching a historical high of 1348.57 billion RMB, driven by the COVID-19 pandemic and favorable policies [4] - The years 2022-2023 marked a deep adjustment period, with financing dropping to 570.04 billion RMB in 2023 due to a conservative investment climate and uncertainties in commercialization [4] Recovery Factors - The recovery in 2025 is attributed to multiple positive factors, including the implementation of the "14th Five-Year Plan" for the bio-economy and the optimization of drug approval processes [5] - Advances in artificial intelligence and synthetic biology are injecting new innovation momentum into the industry, attracting capital back [5] Investment Stage Distribution - The financing landscape in 2025 is characterized by a focus on early to mid-stage investments, with early investments (seed, angel, Pre-A rounds) being particularly active, accounting for 13.1% of total financing events [6][8] - Mid-stage investments dominate the market with a 56.9% share, particularly in A and A+ rounds, indicating a preference for projects with validated core technologies and initial clinical progress [6][8] - Late-stage financing remains cautious, with only 11.5% of financing events occurring in C rounds and beyond, reflecting the high risks associated with clinical development and commercialization uncertainties [6][8] Strategic Investments - There were 69 strategic investments in 2025, accounting for 9.5% of total financing, primarily from large pharmaceutical companies and industrial funds focusing on industry chain collaboration and cutting-edge technology positioning [9]